| Companies sponsors |
Pfizer (tucatinib) |
| Others |
Department of Health and Social Care |
| |
Health Technology Wales |
| Patient carer groups |
Bowel Cancer UK |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Assessment group |
Liverpool Reviews and Implementation Group (LRIG) |
| Associated public health groups |
None |
| Comparator companies |
Bayer (regorafenib) (confidentiality agreement signed, participating) |
| |
Merck Serono (cetuximab) (confidentiality agreement signed, participating) |
| |
Pfizer (folinic acid, fluorouracil, irinotecan, oxaliplatin, raltitrexed, trastuzumab) (confidentiality agreement signed, participating) |
| |
Roche (trastuzumab) (confidentiality agreement signed, participating) |
| |
Servier (trifluridine with tipiracil) (confidentiality agreement signed, participating) |
| |
A H pharmaceuticas (folinic acid, fluorouracil) (confidentiality agreement not signed, not participating) |
| |
Accord (fluorouracil, irinotecan, oxaliplatin, trastuzumab) (confidentiality agreement not signed, not participating) |
| |
Alliance (folinic acid) (confidentiality agreement not signed, not participating) |
| |
Amgen (trastuzumab) (confidentiality agreement not signed, not participating) |
| |
Celtrion (trastuzumab) (confidentiality agreement not signed, not participating) |
| |
Consilient Health (folinic acid, irinotecan, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Fresenius Kabi (folinic acid, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Medac (folinic acid, fluorouracil, irinotecan, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Medihealth (folinic acid) (confidentiality agreement not signed, not participating) |
| |
Organon (trastuzumab) (confidentiality agreement not signed, not participating) |
| |
Pierre Fabre (encorafenib) (confidentiality agreement not signed, not participating) |
| |
Seacross (irinotecan, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Sigma pharmaceuticals (folinic acid) (confidentiality agreement not signed, not participating) |
| |
Sun pharmaceuticals (oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Teva (folinic acid) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
| |
National Institute for Health Research |